SCHEMBL2997602

SCHEMBL2997602

O=S(=O)(c1ccc(Cl)cc1)N1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.69
ALDH1A1 P00352 2/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
MAPK1 P28482 4/20 0.67
LMNA P02545 3/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
MAPT P10636 5/20 0.58
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
RECQL P46063 1/20 0.58
GBA1 P04062 2/20 0.55
AR P10275 3/20 0.55
TP53 P04637 2/20 0.55
ALOX15 P16050 1/20 0.55
RAB9A P51151 6/20 0.54
NPC1 O15118 5/20 0.54
HTT P42858 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011743 0.94 SMN1; SMN2 (0.78) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3012649 0.90 MAPK1 (0.65) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3022487 0.89 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3010921 0.89 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3008299 0.89 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3018895 0.89 SMN1; SMN2 (0.89) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3017643 0.89 SMN1; SMN2 (0.89) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3005995 0.89 MAPK1 (0.64) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3001207 0.88 LMNA (0.70) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3014776 0.88 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.